Panel Discussion: Which Modality to Choose? Debating the Implementation of Biologics vs Small Molecules

Time: 4:45 pm
day: Day One

Details:

  • With only 3 FDA approved antibodies and roughly 20 in development, what are the hurdles to showing efficacy in antibody drug development for GPCRs
  • Will antibodies replace small molecules in the GPCR space?
  • Are there indications where an antibody may fair better or equal to small molecules (oncology space?)

Speakers: